Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Sanchinarro, Spain Clinical Trials

A listing of Sanchinarro, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (563) clinical trials

Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

The duration of the study for 1 patient will include a screening period of up to 21 days prior to first study drug administration, 3-week treatment cycle(s) (until 30 days after last SAR566658 administration), and a follow-up period. Each patient will be treated until radiological disease progression, unacceptable toxicity, or ...

Phase

1.01 miles

Learn More »

Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the ...

Phase

1.01 miles

Learn More »

Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with relapsed or refractory PTCL. Up to 30 subjects may be enrolled in the study. The first 18 subjects may be of the following PTCL sub-types: PTCL, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell ...

Phase

1.01 miles

Learn More »

Phase 2 Study of MLN0128 Combination of MLN0128 With MLN1117 Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer

The drugs being evaluated in this study are MLN0128 and MLN1117. MLN0128 is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination. ...

Phase

1.01 miles

Learn More »

Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients

Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug

Phase N/A

1.01 miles

Learn More »

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

This is an observational, multicenter study in patients treated with nivolumab for the approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the United States (US). Targeted countries in the EU for study participation include Austria, Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). ...

Phase N/A

1.01 miles

Learn More »

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

1.01 miles

Learn More »

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

In the first part of the study (Part 1, dose-escalation), Sym015 will be evaluated for safety and tolerability. Additionally, the recommended phase 2 dose (RP2D) will be determined. Sym015 will be given at different dose levels on an every second week (Q2W) dosing schedule. Each patient will be given one ...

Phase

1.01 miles

Learn More »

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

The study was redesigned to expand the number of patients analyzed during the Phase 1b stage of the study to determine a safe and effective dose of AG-120 administered with azacitidine for future studies. The Phase 1b (AG-120 expansion) stage will evaluate the safety, tolerability, and clinical activity of oral ...

Phase

1.01 miles

Learn More »

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation

The use of highly effective rituximab-containing therapy for treating diffuse large B-cell lymphoma (DLBCL) makes it more difficult to salvage relapsed or refractory patients. In addition, patients with advanced age or significant comorbidities, who are consequently not candidates for high-dose consolidative therapy, have a very poor prognosis. Prospective studies investigating ...

Phase

1.01 miles

Learn More »